Literature DB >> 9008537

Unusual MRI and pathologic findings of progressive multifocal leukoencephalopathy complicating adult Wiskott-Aldrich syndrome.

T Matsushima1, K Nakamura, T Oka, N Tachikawa, T Sata, S Murayama, N Nukina, I Kanazawa.   

Abstract

We present a long-surviving patient with Wiskott-Aldrich syndrome complicated by atypical progressive multifocal leukoencephalopathy (PML). MRI showed multiple tiny spots of Gd-DTPA-enhanced lesions on the T1-weighted image. Pathologic findings for brain biopsy were patchy demyelinated vascularized lesions infiltrated by a surprising number of eosinophils. The presence of polyomavirus JC was confirmed by in situ hybridization and polymerase chain reaction. PML should be included in the differential diagnosis when Gd-DTPA-enhanced spotty lesions are present in the white matter, especially in patients who have a mild immunologic defect.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9008537     DOI: 10.1212/wnl.48.1.279

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  3 in total

Review 1.  Progressive Multifocal Leukoencephalopathy in Primary Immune Deficiencies: Stat1 Gain of Function and Review of the Literature.

Authors:  Christa S Zerbe; Beatriz E Marciano; Rohit K Katial; Carah B Santos; Nick Adamo; Amy P Hsu; Mary E Hanks; Dirk N Darnell; Martha M Quezado; Cathleen Frein; Lisa A Barnhart; Victoria L Anderson; Gulbu Uzel; Alexandra F Freeman; Andrea Lisco; Avindra Nath; Eugene O Major; Elizabeth P Sampaio; Steven M Holland
Journal:  Clin Infect Dis       Date:  2016-01-06       Impact factor: 9.079

2.  Brain damages in ketamine addicts as revealed by magnetic resonance imaging.

Authors:  Chunmei Wang; Dong Zheng; Jie Xu; Waiping Lam; D T Yew
Journal:  Front Neuroanat       Date:  2013-07-17       Impact factor: 3.856

Review 3.  Is there a (host) genetic predisposition to progressive multifocal leukoencephalopathy?

Authors:  Eli Hatchwell
Journal:  Front Immunol       Date:  2015-05-11       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.